SEARCH

SEARCH BY CITATION

References

  • Alvarez-Sanchez F., Brache V., Leon P., Faundes A.. Inhibition of spermatogenesis with monthly injections of medroxyprogesterone acetate and low dose testosterone enanthate. Int J Androl. 1979;2: 136149.
  • Alvarez-Sanchez F., Faundes A., Brache V., Leon P.. Attainment and maintenance of azoospermia with combined monthly injections of depot medroxyprogesterone acetate and testosterone enanthate. Contraception. 1977;15: 635648.
  • Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J Androl. 1999;20: 407414.
  • Anawalt BD, Herbst KL, Matsumoto AM, Mulders TM, Coelingh-Bennink HJ, Bremner WJ. Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression. Fertil Steril. 2000;74: 707714.
  • Anderson RA, Kinniburgh D., Baird DT. Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception. J Clin Enocrinol Metab. 2002;87: 36403649.
  • Bagatell CJ, Heiman J.R., Matsumoto AM, Rivier JE, Bremner WJ. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Enocrinol Metab. 1994;79: 561567.
  • Bain J., Rachlis V., Robert E., Khait Z.. The combined use of oral medroxyprogesterone acetate and methyltestosterone in a male contraceptive trial programme. Contraception. 1980;21: 365379.
  • Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Bremner WJ, Matsumoto AM. Combined administration of levonorgestrel and testosterone induces more rapid effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab. 1996;81: 757762.
  • Behre HM, Kliesch S., Lemcke B., vo Eckardstein S., Nieschlag E.. Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. Hum Reprod. 2001;16: 25702577.
  • Brenner PF, Mishell DR, Bernstein GS, Ortiz A.. Study of medroxyprogesterone acetate and testosterone enanthate as a male contraceptive. Contraception. 1977;15: 679691.
  • Buchter D., vo Eckardstein S., vo Eckardstein A., Kamischke A., Simoni M., Behre HM, Nieschlag E.. Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. J Clin Endocrinol Metab. 1999;84: 12441249.
  • Couzinet B., Young J., Brailly S., Chanson P., Thomas JL, Schaison G.. The antigonadotropic activity of progestins (19-nortestosterone and 19-norprogesterone derivatives) is not mediated through the androgen receptor. J Clin Endocrinol Metab. 1996;81: 42184223.
  • Darney PD. The androgenicity of progestins. Am J Med. 1995;98(1A): 104110.
  • Dixon WJ, Brown MB, Engelman L., Jennrich RI. BMDP statistical software manual. Berkeley, CA: University of California Press; 1990: 739768.
  • Faundes A., Brache V., Leon P., Schmidt F., Alvarez-Sanchez F.. Sperm suppression with monthly injections of medroxyprogesterone acetate combined with testosterone enanthate at a high dose (500 mg). Int J Androl. 1981;4: 235245.
  • Flickinger CJ. The influence of progestin and androgen on the fine structure of the male reproductive tract of the rat. I. General effects and observations on the testis. Anat Rec. 1977a;187: 405430.
  • Flickinger CJ. The influence of progestin and androgen on the fine structure of the male reproductive tract of the rat. II. Epididymis and sex accessory glands. Anat Rec. 1977b;187: 431462.
  • Fogh M., Corker CS, Hunter WM, McLean H., Philip J., Schou G., Skakkebaek NE. The effects of low doses of cyproterone acetate on some functions of the reproductive system in normal men. Acta Endocrinol (Copenh). 1979;91: 545552.
  • Fogh M., Corker CS, McLean H., Hunter WM, Peterson IB, Philip J., Schou G., Skakkebaek NE. Clinical trial with levo-norgestrel and testosterone enanthate for male fertility control. Acta Endocrinol (Copenh). 1980a;95: 251257.
  • Fogh M., Nicol K., Petersen IB, Schou G.. Clinical evaluation of long-term treatment with levo-norgestrel and testosterone enanthate in normal men. Contraception. 1980b;21: 631640.
  • Fogh M., Pedersen D., Gormsen J., Knudsen JB, Schou G.. Oral levonorgestrel testosterone effects on spermatogenesis, hormone levels, coagulation factors and lipoproteins in normal men. Contraception. 1980c;21: 381391.
  • Fredricsson B.. On the development of different morphologic abnormalities of human spermatozoa. Andrologia. 1978;10: 4348.
  • Fredricsson B., Carlstrom K.. Effects of low doses of cyproterone acetate on sperm morphology and some other parameters of reproduction in normal men. Andrologia. 1981;13: 369375.
  • Frick J.. Control of spermatogenesis in men by combined administration of progestin and androgen. Contraception. 1973;8: 191206.
  • Frick J., Bartsch G., Weiske WH. The effect of monthly depot medroxyprogesterone acetate and testosterone on human spermatogenesis. I. Uniform dosage levels. Contraception. 1977a;15: 649668.
  • Frick J., Bartsch G., Weiske WH. The effect of monthly depot medroxyprogesterone acetate and testosterone on human spermatogenesis. II. High initial dose. Contraception. 1977b;15: 669677.
  • Frick J., Danner C., Kunit G., Joos H., Kohle R.. Spermatogenesis in men treated with injections of medroxyprogesterone acetate combined with testosterone enanthate. Int J Androl. 1982;5: 246252.
  • Gao E., Lin C., Gui Y., Li L., He C.. Inhibitine effects of sino-implant plus testosterone undecenoate (TU) on spermatogenesis in Chinese men. Reprod Contracept. 1999;10: 98105.
  • Glasier AF, Anakwe R., Everington D., Martin CW, van Der Spuy Z., Cheng L., Ho PC, Anderson RA. Would women trust their partners to use a male pill? Hum Reprod. 2000;15: 646649.
  • Glasier AF, Smith KB, Cheng L., Ho PC, van Der Spuy Z., Baird DT. An international study on the acceptability of a once-a-month pill. Hum Reprod. 1999;14: 30183022.
  • Gonzalo IT, Swerdloff RS, Nelson AL, Clevenger B., Garcia R., Berman N., Wang C.. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab. 2002;87: 35623572.
  • Guerin JF, Rollet J.. Inhibition of spermatogenesis in men using various combinations of oral progestanges and percutaneous or oral androgens. Int J Androl. 1988;11: 187199.
  • Handelsman DJ, Conway AJ, Howe CJ, Turner L., Mackey MA. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. J Clin Endocrinol Metab. 1996;81: 41134121.
  • Handelsman DJ, Farley TMM, Peregoudov A., Waites GMH, World Health Organization (WHO). Factors in nonuniform induction of azoospermia by testosterone enanthate in normal men. Fertil Steril. 1995;83: 125132.
  • Hikim AP, Wang C., Leung A., Swerdloff RS. Involvement of apoptosis in the induction of germ cell degeneration in adult rats after gonadotropin-releasing hormone antagonist treatment. Endocrinol. 1995;136: 27702775.
  • Johansson EDB, Nygren KG. Depression of plasma testosterone levels in men with norethindrone. Contraception. 1973;8: 219226.
  • Johnson L., Barnard JJ, Rodriguez L., Smith EC, Swerdloff RS, Wang XH, Wang C.. Ethnic differences in testicular structure and spermatogenic potential may predispose testes of Asian men to a heightened sensitivity to steroidal contraceptives. J Androl. 1998;19: 348357.
  • Kamischke A., Diebacker J., Nieschlag E.. Potential of norethisterone enanthate for male contraception: pharmacokinetics and suppression of pituitary and gonadal function. Clin Endocrinol (Oxf). 2000a;53: 351358.
  • Kamischke A., Heuermann T., Kruger K., vo Eckardstein S., Schellschmidt I., Rubig A., Nieschlag E.. An effective hormonal male contraceptive using testosterone undecenoate with oral or injectable norethisterone preparations. J Clin Endocrinol Metab. 2002;87: 530539.
  • Kamischke A., Ploger D., Venherm S., vo Eckardstein S., vo Eckardstein A., Nieschlag E.. Intramuscolar testosterone undecenoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception. Clin Endocrinol (Oxf). 2000b;53: 4352.
  • Kamischke A., Venherm S., Ploger D., vo Eckardstein S., Nieschlag E.. Intramuscular testosterone undecenoate and norethisterone enanthate in a clinical trial for male contraception. J Clin Endocrinol Metab. 2001;86: 303309.
  • Kinniburgh D., Anderson RA, Baird DT. Suppression of spermatogenesis with desogestrel and testosterone pellets is not enhanced by addition of finasteride. J Androl. 2001;22: 8895.
  • Kinniburgh D., Zhu H., Cheng L., Kicman AT, Baird DT, Anderson RA. Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men. Hum Reprod. 2002;17: 14901501.
  • Knuth UA, Yeung CH, Nieschlag E.. Combination of 19-nortestosteronehexyloxyphenylpropionate (Anadur) and depot-medroxyprogesterone-acetate (Clinovir) for male contraception. Fertil Steril. 1989;51: 10111018.
  • Koch UJ, Lorenz F., Danehl K., et al. Continuous oral low-dosage cyproterone acetate for fertility regulation in the male? A trend analysis in 15 volunteers. Contraception. 1976;14: 117135.
  • Kuhnz W., Heuner A., Humpel M., Seifert W., Michaelis K.. In vivo conversion of norethisterone and norethisterone acetate to ethinyl estradiol in postmenopausal women. Contraception. 1997;56: 379385.
  • Lee HY, Kim SI, Kwon EH. Clinical trial on reversible male contraception with long-acting sex hormones. Seoul J Med. 1979;20: 199216.
  • Lobel B., Olivo JF, Guille F., le Lannou D.. Contraception in men: efficacy and immediate toxicity. A study of 18 cases. Acta Urol Belg. 1989;57: 117124.
  • Lobl TJ, Musto NA, Gunsalus GL, Bardin CW. Medroxyprogesterone acetate has opposite effects on the androgen binding protein concentrations in serum and epididymis. Biol Reprod. 1983;29: 697712.
  • Lohiya NK, Sharma OP. Effects of cyproterone acetate with combination of testosterone enanthate on seminal characteristics, androgenicity and clinical chemistry in langur monkey. Contraception. 1983;28: 575586.
  • Lookingbill DP, Demers LM, Wang C., Leung A., Rittmaster RS, Santen RJ. Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J Clin Endocrinol Metab. 1991;72: 12421248.
  • Martin CW, Anderson RA, Cheng L., et al. Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. Hum Reprod. 2000;15: 637645.
  • Matsumoto AM. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production. J Clin Endocrinol Metab. 1990;70: 282287.
  • Mauvais-Jarvis P., Kuttenn F., Baudot N.. Inhibition of testosterone conversion to dihydrotestosterone in men treated percutaneously by progesterone. J Clin Endocrinol Metab. 1974;38: 142147.
  • McEwen BS, Davis PG, Gerlach JL, Krey LC, MacLusky NJ, McGinnis MY, Parsons B., Rainbow TC. In: Bardin CW, Milgrom E., Mauvais-Jarvis P., eds. Progesterone and Progestins. New York: Raven Press; 1983: 5976.
  • McLachlan RI, O'Donnell L., Stanton PG, Balourdos G., Frydenberg M., de Kretser DM, Robertson DM. Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men. J Clin Endocrinol Metab. 2002;87: 546556.
  • Melo JF, Coutinho EM. Inhibition of spermatogenesis in men with monthly injections of medroxyprogesterone acetate and testosterone enanthate. Contraception. 1977;15: 627634.
  • Meriggiola MC, Bremner WJ. Progestin-androgen combination regimens for male contraception. J Androl. 1997;18: 240244.
  • Meriggiola MC, Bremner WJ, Costantino A., et al. Twenty-one day administration of dienogest reversibly suppresses gonadotropins and testosterone in normal men. J Clin Endocrinol Metab. 2002a;87: 21072113.
  • Meriggiola MC, Bremner WJ, Costantino A., Di Cintio G., Flamigni C.. Low dose of cyproterone acetate and testosterone enanthate for contraception in men. Hum Reprod. 1998;13: 12251229.
  • Meriggiola MC, Bremner WJ, Costantino A., Pavani A., Capelli M., Flamigni C.. An oral regimen of cyproterone acetate and testosterone undecenoate for spermatogenic suppression in men. Fertil Steril. 1997;68: 844850.
  • Meriggiola MC, Bremner WJ, Paulsen CA, et al. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J Clin Endocrinol Metab. 1996;81: 30183023.
  • Meriggiola MC, Costantino A., Bremner WJ, Morselli-Labate AM. Higher testosterone dose impairs sperm suppression induced by a combined androgen-progestin regimen. J Androl. 2002b;23: 684690.
  • Meriggiola MC, Marcovina S., Paulsen CA, Bremner WJ. Testosterone enanthate at a dose of 200 mg/week decreased HDL-cholesterol levels in healthy men. Int J Androl. 1995;18: 237242.
  • Moltz L., Rommler A., Post K., Schwartz U., Hammerstein J.. Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men. Contraception. 1980;21: 393413.
  • Morse HC, Leach DR, Rowley MJ, Heller CG. Effect of cyproterone acetate on sperm concentration, seminal fluid volume, testicular cytology and levels of plasma and urinary ICSH, FSH and testosterone in normal men. J Reprod Fertil. 1973;32: 365378.
  • Hair W Morton, Kitteridge K., O'Connor DB, Wu FCW. A novel male contraceptive pill-patch combination: oral desogestrel and transdermal testosterone in the suppression of spermatogenesis in normal men. J Clin Endocrinol Metab. 2001;86: 52015209.
  • Neumann F., vo Berswordt-Wallrabe R.. Effects of the androgen antagonist cyproterone acetate on the testicular structure, spermatogenesis and accessory sexual glands of testosterone-treated adult hypophysectomized rats. J Endocrinol. 1966;35: 363371.
  • Nieschlag E., Behre HM. Testosterone in male contraception. In: Nieschlag E., Behre HM, eds. Testosterone Action-Deficiency-Substitution. Berlin: Springer-Verlag; 1998: 513528.
  • Norusis M.. SPSS/PC+: Base system user's guide; advanced statistics, version 5.0. Chicago: SPSS Inc; 1992.
  • Pangkahila W.. Reversible azoospermia induced by an androgen-progestin combination regimen in Indonesian men. Int J Androl. 1991;14: 248256.
  • Paulsen CA, Leach RB, Lanman J., Goldston N., Maddock WO, Heller CG. Inherent estrogenicity of Norethindrone and Norethynodrel: comparison with other synthetic progestins and progesterone. J Clin Endocrinol Metab. 1962;XXII: 10331039.
  • Paulsen CA, Leonard JM, Bremner WJ. The use of androgens, androgen-danazol or androgen-progestagen combinations for the regulation of male fertility. In: Proceedings of the VI International Congress of Endocrinology. Melbourne, Australia: Griffin Press Ltd; 1980.
  • Petry R., Mauss J., Rausch-Stroomann JG, Vermeulen A.. Reversible inhibition of spermatogenesis in men. Horm Metab Res. 1972;4: 386388.
  • Pollanen P., Nikkanen V., Huhtaniemi I.. Combination of subcutaneous levonorgestrel implants and transdermal dihydrotestosterone gel for male hormonal contraception. Int J Androl. 2001;24: 369380.
  • Pugeat MM, Dunn JF, Nisula BC. Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab. 1981;53: 6975.
  • Ringheim K.. What have we learned about the acceptability of fertility regulation methods used by men? Male contraception: present and future. In: Rajalakshmi M., Griffin PD, eds. Male Contraception: Present and Future. New Delhi: New Age International; 1999.
  • Roy S., Chatterjee S.. The role of antiandrogenic action in cyproterone acetate-induced morphologic and biochemical changes in human semen. Fertil Steril. 1979;32: 9395.
  • Roy S., Chatterjee S., Prasad MR, Poddar AK, Pandey DC. Effects of cyproterone acetate on reproductive functions in normal human males. Contraception. 1976;14: 403420.
  • Roy S., Prasad RD. Biological and clinical research on male reproduction and fertility regulation. J Biosci. 1985;7: 229243.
  • Santner SJ, Albertson B., Zhang GY, et al. Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects. J Clin Endocrinol Metab. 1998;83: 21042109.
  • Schering AG. Schering AG and Organon join forces in male contraception [press release]. Available at http:www.schering.deengindex.html. Accessed November 21, 2002.
  • Sinha AP, Wang C., Lue Y., Johnson L., Wang XH, Swerdloff RS. Spontaneous germ cell apoptosis in humans: evidence for ethnic differences in the susceptibility of germ cells to programmed cell death. J Clin Endocrinol Metab. 1998;83: 152156.
  • Soufir JC, Jouannet P., Marson J., Soumah A.. Reversible inhibition of sperm production and gonadotropin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment. Acta Endocrinol (Copenh). 1983;102: 625632.
  • Srivastava UK. Long-term regulation of male fertility by norethisterone enanthate “epididymal” implants: effect on libido and fertility of rabbits. Indian J Physiol Pharmacol. 1981;25: 158162.
  • Srivastava UK, Malaviya B.. Effect of chronic local administration of norethisterone enanthate on the testes of adult rat. Indian J Physiol Pharmacol. 1980;24: 4955.
  • Steinbeck H., Mehring M., Neumann F.. Comparison of the effects of cyproterone, cyproterone acetate and oestradiol on testicular function, accessory sexual glands and fertility in a long-term study on rats. J Reprod Fertil. 1971;26: 6576.
  • Suhana N., Moeloek N Sutyarso, Soeradi O., Sukmaniah SS, Supriatna J.. The effects of feeding an Asian or Western diet on sperm numbers, sperm quality and serum hormone levels in cynomolgus monkeys (Macaca fascicularis) injected with testosterone enanthate (TE) plus depot medroxyprogesterone acetate (DMPA). Int J Androl. 1999;22: 102112.
  • Swerdloff RS, Bagatell CJ, Wang C., Anawalt BD, Berman N., Steiner B., Bremner WJ. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. J Clin Endocrinol Metab. 1998;83: 35273533.
  • Terner C., MacLaughlin J.. Effects of sex hormones on germinal cells of the rat testis: a rationale for the use of progestin and androgen combinations in the control of male fertility. J Reprod Fertil. 1973;32: 453464.
  • Vreeburg JT, Bielska M., Ooms M.. Maturation and survival of spermatozoa in the epididymis of pregnenolone treated hypophysectomized rats. Endocrinology. 1976;99: 824830.
  • Wang C., Berman NG, Veldhuis JD, Der T., McDonald V., Steiner B., Swerdloff RS. Graded testosterone infusions distinguish gonadotropin negative-feedback responsiveness in Asian and White-men—a clinical research center study. J Clin Endocrinol Metab. 1998;83: 870876.
  • Wang C., Yeung KK. Use of low-dosage oral cyproterone acetate as a male contraceptive. Contraception. 1980;21: 245272.
  • Weinbauer GF, Gockeler E., Nieschlag E.. Testosterone prevents complete suppression of spermatogenesis in the gonadotropin-releasing hormone antagonist-treated non-human primate (Macaca Fascicularis). J Clin Endocrinol Metab. 1988;67: 284290.
  • World Health Organization (WHO). Task force on methods for the regulation of male fertility contraceptive. Efficacy of testosterone-induced azoospermia in normal men. Lancet. 1990;336: 955959.
  • World Health Organization (WHO). Comparison of two androgens plus depot-medroxyprogesterone acetate for suppression to azoospermia in Indonesian men. Fertil Steril. 1993;60: 10621068.
  • World Health Organization (WHO) Task Force on Methods for the Regulation of Male Fertility Contraceptive. Efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril. 1996;65: 821829.
  • Worgul T., Baker HWG, Murray FT, Jefferson LS, Bardin GW. Direct effects of medroxyprogesterone acetate on testes: possible mechanism examined by testicular perfusion. Int J Androl. 1979;2: 408418.
  • Wu FCW, Aitken RJ. Suppression of sperm function by depot medroxyprogesterone acetate and testosterone enanthate in steroid male contraception. Fertil Steril. 1989;51: 691698.
  • Wu FCW, Balasubramanian R., Mulders TMT, Coelingh-Bennink HJT. Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis and lipid metabolism. J Clin Endocrinol Metab. 1999;84: 112122.
  • Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ. A clinical trial of injectable testosterone undecenoate as a potential male contraceptive in normal Chinese men. J Clin Endocrinol Metab. 1999;84: 36423647.